Related references
Note: Only part of the references are listed.Diagnosis and management of pemphigus: Recommendations of an international panel of experts
Dedee F. Murrell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up
Vinod K. Sharma et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study
Irene Russo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Long-term outcomes of rituximab therapy in pemphigus
I Shimanovich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy A Post Hoc Analysis of a Randomized Clinical Trial
Claire Mignard et al.
JAMA DERMATOLOGY (2020)
The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: Daily practice data from a retrospective study
Hanan Rashid et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
P. Joly et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up
Dipankar De et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2020)
Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
Carolyn J. Kushner et al.
JAMA DERMATOLOGY (2019)
Clinical and immunological features of pemphigus relapse
I Ujiie et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review
Soheil Tavakolpour et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center
Keshavamurthy Vinay et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab
Marwah Adly Saleh
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing
Christian Schoergenhofer et al.
SCIENTIFIC REPORTS (2018)
Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab
Kamran Balighi et al.
DERMATOLOGIC THERAPY (2018)
Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients
Aaron J. Robinson et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2018)
Safety profile of biological therapies for treating rheumatoid arthritis
Juan D. Canete et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Low-dose rituximab as an adjuvant therapy in pemphigus
Jaya Gupta et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2017)
Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up
Tae Hyung Kim et al.
JOURNAL OF DERMATOLOGY (2017)
Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab
Lauren N. Albers et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Pascal Joly et al.
LANCET (2017)
Rituximab in the treatment of 38 patients with Pemphigus with long-term follow-up
S. Currimbhoy et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey
Soner Uzun et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens
Hsiao-Han Wang et al.
ACTA DERMATO-VENEREOLOGICA (2015)
A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab
A. Razzaque Ahmed et al.
AUTOIMMUNITY REVIEWS (2015)
Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study
A. J. Kanwar et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Pilot Study of 19 Patients with Severe Pemphigus: Prophylactic Treatment with Rituximab Does Not Appear to be Beneficial
S. Gregoriou et al.
DERMATOLOGY (2014)
Durable Remission of Pemphigus With a Fixed-Dose Rituximab Protocol
Kara Heelan et al.
JAMA DERMATOLOGY (2014)
Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases
Sharon Baum et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus A Case Series of 9 Patients
Setsuko Matsukura et al.
ARCHIVES OF DERMATOLOGY (2012)
Adjuvant Rituximab Therapy of Pemphigus
Luisa Lunardon et al.
ARCHIVES OF DERMATOLOGY (2012)
Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy
R. J. Feldman et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Low-dose rituximab is effective in pemphigus
B. Horvath et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up
Ziad Reguiai et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up
Giuseppe Cianchini et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Rituximab in Severe Pemphigus
Enno Schmidt et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
ELISA Testing of Anti–Desmoglein 1 and 3 Antibodies in the Management of Pemphigus
Claire Abasq et al.
ARCHIVES OF DERMATOLOGY (2009)
Immunogenicity of rituximab in patients with severe pemphigus
Enno Schmidt et al.
CLINICAL IMMUNOLOGY (2009)
Rituximab in refractory pemphigus vulgaris
M. Sorce et al.
DERMATOLOGIC THERAPY (2008)
Treatment of refractory pemphigus erythematosus with rituximab
Mohammad Diab et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2008)
Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris
Annesofie Faurschou et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2008)
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases
Michael Hertl et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2008)
B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses
Hugo Mouquet et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
Dedee E. Murrell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Treatment failure with rituximab in a patient with pemphigus vulgaris
W. Weger et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2008)
Successful treatment of recalcitrant pemphigus foliaceus with rituximab
V. V. Serrao et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2008)
Treatment of severe pemphigus foliaceus with rituximab
Suran L. Fernando et al.
MEDICAL JOURNAL OF AUSTRALIA (2008)
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2007)
Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients
M. S. Y. Goh et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): Five cases
Angela Antonucci et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2007)
Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
Angelo V. Marzano et al.
DERMATOLOGY (2007)
Rituximab in refractory autoimmune bullous diseases
E. Schmidt et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2006)
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
MJ Arin et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)
A Dupuy et al.
ARCHIVES OF DERMATOLOGY (2004)
Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder
TG Salopek et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Share Paper
